Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

IMA new masthead1

Internal Medicine Alert – October 30, 2010

October 30, 2010

View Archives Issues

  • Is Statin Therapy Ever Indicated in Young Adults?

    Initiating treatment for hypercholesterolemia at age 30 years instead of age 60 years might very well prevent not just 30% of the CAD events as occurred in the 5-year statin trials, but perhaps as many as 60% of the CAD events lifetime.
  • What's Best for the Breast?

    In a very large Norwegian study, use of screening mammography was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for only about a third of the total reduction in death rate.
  • Could that Persistent Cough Be Pertussis? Don't Rely on the Whoop

    A systematic review shows that the three classical symptoms of paroxysmal cough, post-tussive emesis, and inspiratory whoop are helpful for the diagnosis, but cannot be relied upon to rule in or rule out pertussis as the cause of a chronic cough.
  • Pegloticase Injection (Krystexxa™)

    A recombinant, polyethylene glycol (PEG) mammalian urate oxidase (uricase) has been approved by the FDA for treatment of hyperuricemia. Uricase metabolizes urate to allantoin, a water-soluble metabolite, which is cleared renally. Pegliticase is marketed by Savient Pharmaceuticals as Krystexxa™.
  • Clinical Briefs by Louis Kuritzky, MD

    The incretin class of medications (exenatide, liraglutide, sitagliptin, saxagliptin) all share the favorable quality of not being associated with weight gain.